Thiamine-responsive megaloblastic anaemia: a cause of syndromic diabetes in childhood

Pediatr Diabetes. 2007 Aug;8(4):239-41. doi: 10.1111/j.1399-5448.2007.00251.x.


Thiamine-responsive megaloblastic anaemia (TRMA) is a rare autosomal recessive condition, characterized by megaloblastic anaemia, non-autoimmune diabetes mellitus, and sensorineural hearing loss. We describe three infants with TRMA from two consanguineous Pakistani families, who were not known to be related but originated from the same area in Pakistan. All children were homozygous, and the parents were heterozygous for a c.196G>T mutation in the SLC19A2 gene on chromosome 1q23.3, which encodes a high-affinity thiamine transporter. The result is an abnormal thiamine transportation and vitamin deficiency in the cells. Thiamine in high doses (100-200 mg/d) reversed the anaemia in all our patients. Two patients discontinued insulin treatment successfully after a short period, while the third patient had to continue with insulin. The hearing loss persisted in all three children. The diagnosis of TRMA should be suspected in patients with syndromic diabetes including hearing loss and anaemia, even if the latter is only very mild and, particularly, in the case of consanguinity.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Megaloblastic / drug therapy*
  • Anemia, Megaloblastic / etiology*
  • Child, Preschool
  • Consanguinity
  • DNA Mutational Analysis
  • Diabetes Complications / drug therapy*
  • Diabetes Mellitus / genetics*
  • Female
  • Hearing Loss, Sensorineural / etiology*
  • Homozygote
  • Humans
  • Infant
  • Male
  • Membrane Transport Proteins / genetics*
  • Pakistan / ethnology
  • Thiamine / therapeutic use*


  • Membrane Transport Proteins
  • SLC19A2 protein, human
  • Thiamine